Syndax Pharmaceuticals (SNDX)
(Real Time Quote from BATS)
$20.50 USD
-0.24 (-1.16%)
Updated Apr 18, 2024 02:38 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SNDX 20.50 -0.24(-1.16%)
Will SNDX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SNDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNDX
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
Syndax (SNDX) is on the Move, Here's Why the Trend Could be Sustainable
SNDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates
Syndax Pharmaceuticals (SNDX) Dips More Than Broader Markets: What You Should Know
Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know
Other News for SNDX
Syndax management to meet with BTIG
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
Syndax management to meet with BTIG
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), Inozyme Pharma (INZY) and PTC Therapeutics (PTCT)
Syndax management to meet with BTIG